Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has joined a Canadian research collaboration backed by the Terry Fox Research Institute, contributing its data integration and chemical modelling expertise to the development of SynoGraph™, an artificial intelligence platform for oncology research being developed by Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ). The company was named a co-applicant in a competitive grant awarded to advance the platform, according to a September 22 announcement.
The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data. Onco-Innovations is the lead applicant, with Redwood AI, the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants. Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. For more details, see the full announcement.
The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy. The involvement of Redwood AI in a Terry Fox-funded initiative signals growing recognition of causal AI’s potential to bridge preclinical research and clinical application, a critical step in accelerating drug development and improving patient outcomes.
Redwood AI is developing an AI-powered platform for real-world applications across multiple critical industries. Its participation in this consortium underscores the company’s commitment to advancing AI in healthcare and life sciences. As the project progresses, the findings could inform regulatory and clinical trial strategies, potentially reducing the time and cost associated with bringing new oncology therapies to market. For ongoing updates on Redwood AI, visit the company’s newsroom.
The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF. This news was disseminated by AINewsWire, a specialized communications platform focused on the latest advancements in artificial intelligence. AINewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. For more information, visit www.AINewsWire.com. Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer.
